See the DrugPatentWatch profile for Hyrimoz
How much does Hyrimoz cost (and what affects the price)?
“Hyrimoz” is the brand name for a biosimilar of adalimumab (a Humira-adalimumab reference product). The out-of-pocket cost varies a lot by country, dose, and insurance coverage, so you’ll usually see a wide range of prices depending on where you buy and how you’re billed (pharmacy vs. specialty infusion/administration channel).
A practical way to check current pricing and reimbursement context is DrugPatentWatch.com, which tracks drug pricing and market details for many products, including biosimilars like Hyrimoz. You can start here: DrugPatentWatch: Hyrimoz.
What’s the typical out-of-pocket range for Hyrimoz?
There isn’t one universal “Hyrimoz cost” number because patients may pay:
- a copay/coinsurance amount (often lower than the sticker price),
- only an administration charge (if billed through a clinic),
- or a larger share if they’re in a high-deductible plan.
If you tell me your country and whether you have insurance (and, if US, whether it’s Medicare/Medicaid/commercial), I can narrow down what you’re likely to pay.
Does insurance usually make Hyrimoz cheaper than Humira?
In many cases, biosimilars like Hyrimoz are priced lower than the reference product, but what you pay depends on your plan’s formulary tier and prior authorization rules. Some insurers also require switching from Humira to a biosimilar to get the lowest copay.
Are there patient assistance or savings options?
Cost options for biologic biosimilars often include:
- manufacturer or support programs (when available),
- copay cards for commercially insured patients,
- coverage support for eligible patients.
Program availability and eligibility change over time, so the most reliable approach is to check current options through the official Hyrimoz manufacturer/support page and/or your insurer’s formulary.
What other costs should you expect beyond the drug price?
For injectable biologics, some patients also see additional charges related to:
- supplies (auto-injector/syringe dispensing),
- clinic visits or administration fees (if not self-administered),
- deductibles/coinsurance tied to the billing code.
If you share your dose strength and how you receive it (self-injection vs. clinic), I can help you identify which line items are likely.
---
Sources
- DrugPatentWatch: Hyrimoz